Talphera, Inc.
TLPH Healthcare Drug Manufacturers Specialty & Generic
In the quarter to June 2026, revenue fell 99.6%, EPS grew 40.0% and free cash flow fell 33.1%, each against the same quarter a year earlier. Operating cash flow growth for five consecutive years; insiders bought in the last twelve months.
Follow TLPH
Talphera, Inc. (TLPH) P/E ratio
Talphera, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 1.2× (August 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.3× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2025 | 0.0× | — |
| Mar 2025 | 0.0× | — |
| Dec 2023 | 0.0× | — |
| Sep 2023 | 0.0× | — |
| 33 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| SCYX SCYNEXIS, Inc. compare | n/m |
| IXHL Incannex Healthcare Inc. compare | n/m |
| CTOR Citius Oncology, Inc. compare | n/m |
| CLVR Clever Leaves Holdings Inc. compare | n/m |
| CPHI China Pharma Holdings, Inc. compare | n/m |
| RMTI Rockwell Medical, Inc. compare | n/m |
| TLPH Talphera, Inc. | n/m |
| INCR InterCure Ltd. compare | 8.8× |
| ZYBT Zhengye Biotechnology Holding Limited compare | — |
| Drug Manufacturers Specialty & Generic industry median | 19.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)